Puma Biotech anti-HER2 breast cancer drug approved in China - BioTuesdays
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Articles about Puma Biotechnology
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotech granted Orphan Drug status for lung cancer candida | Seeking Alpha
Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High | Investor's Business Daily
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotech Surges, Defying Yellen
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech punts near $300 million on Takeda discard
Puma Biotech Defies Odds, Wins FDA Backing for Breast Cancer Drug | BioSpace
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain Stock
Puma Biotech plunges on drug side effects
/cloudfront-us-east-2.images.arcpublishing.com/reuters/VE4SVIOXA5KJLBYGVH2UMAY3SY.jpg "Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters")
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
